Lacosamid Stada

Lacosamide, the active ingredient in Lacosamid Stada, is an antiepileptic presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures, used as adjunctive therapy in patients with epilepsy who require additional seizure control.

GNH USA supplies Lacosamid Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets across Europe, Asia and the Americas through established distribution networks.

Lacosamide is an antiepileptic drug used in the management of focal seizure disorders.

Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic therapy. Adjunctive therapy for epilepsy: improves overall seizure control in patients not fully controlled by monotherapy. Focal epilepsy: provides additional seizure suppression as part of combination treatment.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Fatigue - Nausea - Headache - Diplopia or blurred vision - Tremor

Serious or Rare Side Effects: - Suicidal thoughts or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Cardiac conduction abnormalities, including PR‑interval prolongation - Respiratory depression in susceptible individuals - Anaphylactic reactions

When prescribing Lacosamide, clinicians should consider several safety aspects.

Renal impairment: adjust dose or monitor renal function. Hepatic impairment: evaluate liver enzymes and consider dose modification. Cardiac conduction disorders: caution due to potential PR‑interval prolongation. Pregnancy: category C; discuss risks versus benefits with the patient. Concomitant use with other antiepileptics: monitor for additive effects and plasma level changes. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Lacosamide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Carbamazepine: may lower lacosamide plasma concentrations. - Phenytoin: may reduce lacosamide levels. - Phenobarbital: can decrease lacosamide exposure.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation. - Alcohol: can increase central nervous system effects. - Other sodium‑channel blockers (e.g., lamotrigine): potential additive anti‑seizure effect.